Despite limited success with cannabis in reducing eye pressure for glaucoma patients, Skye Bioscience has shifted focus from eye drops to developing a drug for weight loss. The drug targets the endocannabinoid system and aims to block CB1 receptors to promote weight loss, similar to a previous drug that was withdrawn due to safety concerns. Skye’s drug, nimacimab, is an antibody that may offer safer and more effective weight loss results compared to small molecule drugs. The company has shifted resources to focus on metabolic research, with a Phase 2 study for nimacimab in obesity expected to yield results by late 2025.
Source link
Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program
